Congratulations to Paula Brown Stafford, newly appointed CEO of Allucent! Paula succeeds Mark A. Goldberg, MD, who spearheaded Allucent’s transformation into a global CRO serving mid-size #biopharmaceutical businesses following its partnership with Water Street in 2018. With more than 35 years of #lifesciences experience, including at Quintiles (now IQVIA), Paula will spearhead the next phase of Allucent’s strategic expansion. Please join us in extending a warm welcome to Paula and thanking Mark, who will continue to serve as chairman of the board. To read more, click here: https://lnkd.in/g7F2eHEA
Water Street Healthcare Partners’ Post
More Relevant Posts
-
CFO & VP Supply Chain @ Fresenius Kabi Oncology India I Ex- Baxter I Danone I McCormick I CA 40 under 40
Looking forward for an insightful discussion and knowledge sharing with other esteemed industry experts from pharma industry
We're delighted to introduce one of our distinguished speakers for the ET Future-Ready Pharma Supply Chain Summit - Rahul Sharma, Chief Financial Officer & VP Supply Chain at Fresenius Kabi Oncology Limited! Join us as Rahul shares his expertise and insights into navigating the dynamic landscape of pharmaceutical supply chains. Don't miss this exclusive opportunity to learn from a leader shaping the future of the industry. Register Now: https://bitly.ws/34Mps #ETPharmaSupplyChainSummit #SupplyChainSummit #ETPharmaSupplyChain #PharmaSummit2023 #HealthcareInnovation #Mumbai #InnovationInSupplyChain
To view or add a comment, sign in
-
-
Discover how Ingenious e-Brain’s strategic insights enabled a pharmaceutical company to effectively position Drug X for optimal pricing and acceptance in the competitive oncology market. Our evidence-based approach guided the client through complex pricing strategies, ensuring the successful navigation of payer expectations. Read the detailed case study to explore further: https://lnkd.in/dfFmCE_U #pharmastrategy #oncologymarket #drugpricing #payerstrategy #pharmaceuticals #marketaccess #evidencebased #healthcareconsulting #pricingstrategy #pharmacasestudy #futureproofingbusinesses
To view or add a comment, sign in
-
-
From suprachoroidal injectors and sustained release implants to systemic drugs and eye drops for retinal disorders, the Ophthalmic Drug Delivery meeting has all bases covered for you and your team. For more information on how you can get involved and revolutionize your longer lasting and less invasive retinal drug delivery mechanisms! #ophthalmology #retina #retinaldelivery #suprachoroidal #subretinal #sustainedrelease
Last chance to save up to $950 for the Next Generation Ophthalmic Drug Delivery Summit ❗ View the full list of 23+ expert speakers as they discuss new ways to develop longer lasting and less invasive delivery mechanisms: https://ter.li/i8e0bv Don’t miss out on the only industry-dedicated event focusing on overcoming key translational challenges of developing and implementing novel delivery, with discussions from the likes of Genentech, AbbVie, Novartis, The Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, Boehringer Ingelheim and more! Ready to join 90+ ophthalmic experts? Book your pass before the discounts expire this Friday, December 15: https://ter.li/az6lsk
To view or add a comment, sign in
-
-
CEO of Capptoo Life Science and CXO at CX Advisory - Leading a team of +100 People that help you to drive CX Strategies, Innovation and Results | 25+ Years in Pharma, Healthcare, and FMCG | CX, AI and VoC practitioner
If you keep up with pharmaceutical news, then you’ll know about the bad news for those suffering from ALS… Amylyx Pharmaceuticals has been hard at work attempting to refine its drug, Relyvrio, which was poised to be a significant breakthrough in the treatment of ALS. However, after some impressive early trial results that suggested a potential to slow disease progression, the drug’s journey took an unexpected turn after the latest round of trials when it failed to meet its primary and secondary endpoints. These events have not only impacted Amylx’s market standing, as it experienced a significant drop in share value but also resonated deeply with the ALS community, which had placed high hopes on Relyvrio. If you’d like to hear more about this story, you can click on the link below to read the article I’ve written about it. https://lnkd.in/d3Sx9T6X #CXAdvisory #CX #CXInsights #Personalization
To view or add a comment, sign in
-
-
MBA Pharmaceutical Management,NIPER Hyderabad | Former Intern at Dabur | Former Intern at TheraTraQ | M.Pharm (Pharmaceutics) | B.Pharm
💥AbbVie acquired Landos Biopharma in a deal announced on March 25, 2024. The acquisition bolsters AbbVie's presence in the autoimmune and inflammatory diseases space. 🌞Focus: Landos is a clinical-stage biopharmaceutical company developing novel oral therapies for autoimmune diseases. 🌞Key Asset: AbbVie gains access to Landos' lead drug candidate, NX-13, a first-in-class treatment for ulcerative colitis. 🌞Deal Value: AbbVie agreed to pay $20.42 per share for Landos, amounting to roughly $137.5 million upfront. Additionally, there's a potential milestone-based payment of up to $75 million. Overall, this acquisition strengthens AbbVie's portfolio in a key therapeutic area and brings a promising drug candidate for ulcerative colitis under their wing. #AbbVie #Landos #Acquisition #BioPharma #Healthcare #LifeSciences #MedicalTechnology #Pharmaceuticals #inflammatory
To view or add a comment, sign in
-
-
In Low and Middle Income Countries (LMICs), the challenge isn't just affordability but also the availability of safe, high-quality, and efficacious life-saving pharmaceutical products. Access to these products remains a significant issue, particularly in oncology. My question to industry experts and policymakers: What steps can we take to address this challenge?
To view or add a comment, sign in
-
-
Ever wondered how to navigate the complex landscape of advisors, consultants, collaborators, and partners in the pharmaceutical industry? Sharon Cunningham, CEO and Founder of Shorla Oncology shares invaluable insights on successful partnerships and collaborations. "Spending time really understanding if the potential partner shares your values as a company and ensuring that there's chemistry there from the beginning because otherwise, it's not going to work." That's where EVERSANA COMPLETE Commercialization shines! We not only bring expertise and industry knowledge but also prioritize the chemistry and alignment of values with our partners. Learn more: https://ow.ly/cGxh50QFks2 #CommercializationSuccess #COMPLETECommercialization #EVERSANAPartnership
To view or add a comment, sign in
-
The global dry eye disease market is expected to reach $8884.34 million by 2032, growing at a CAGR of 5.11% during the forecast period, 2023-2032. The introduction of novel diagnostic techniques for dry eye disease plays an essential role in bolstering market growth. Some of the major players operating in the global dry eye disease market are Bausch Health Companies, Allergan Plc (Acquired by AbbVie), Otsuka Pharmaceutical Co Ltd, and others. Request a FREE sample here: https://lnkd.in/dsZkJNV8 . . . AFT Pharmaceuticals Alcon OASIS Medical Otsuka Pharmaceutical Co., Ltd. #dryeyedisease #dryeyes #healthcare #medicaldevices #diagnostics #eyedrops #didyouknow #marketresearch #inkwoodresearch
To view or add a comment, sign in
-
-
Looking forward to our Deep Dive at the health.tech conference in Munich together with Luisa Wasilewski, Jonas Albert and Sebastian Cornelius Retter: 🔈 Beyond the Pill is Dead, Long Live DTx Plus Pill! The New Generation of DTx and Pharma-Cooperations – DiGA and Beyond 📃 This session will explore and discuss three specific use cases, far off the beaten path of what is usually mentioned when it comes to the interplay of digital health and pharmaceutical products. The use cases will feature (1) digital therapeutics of higher risk classes (IIb) and their impact on established therapies, (2) Telemonitoring with a combination DiGAs and Drugs as well as options for digital therapeutics outside of the current reimbursement pathways by acting as leverage for the prescription-volume of pharmaceutical products. 📅 Jun 5, 11:15 AM - 12:00 PM regenold GmbH I dtXca I JensonR+ Limited I DigiHealthStart.NRW I Ute Wenning
To view or add a comment, sign in
-